Business
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary fibrosis (IPF). The findings, which appear online in the Annals of the American Thoracic Society (AnnalsATS), suggest that use of the test increases diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy, while also reducing invasive and potentially risky surgical lung biopsies (SLBs). Findings from the study were previously presented at the CHEST Annual Meeting 2021 in October.\n\nVeracyte estimates that each year in the United States and Europe approximately 200,000 patients have unclear results following evaluation for suspected interstitial lung diseases (ILDs), including IPF, which is among the most common, deadly and difficult to diagnose of these lung-scarring diseases. The Envisia classifier is a highly accurate, clinically validated molecular test that detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other ILDs.\n\n“IPF and other ILDs are often challenging to diagnose, yet a correct and timely diagnosis is a critical first step to support more effective treatment for patients,” said Joseph Lasky, M.D., professor and Pulmonary/Critical Care Section Chief at Tulane University School of Medicine and lead author of the paper. “Our findings demonstrate the clinical utility of the Envisia classifier by increasing the number of IPF diagnoses and associated confidence in those diagnoses, while avoiding more-invasive procedures. Importantly, use of the genomic test in the diagnostic work-up also led to increased recommendation for antifibrotic therapies, which have been shown to improve outcomes of patients with IPF.”\n\nFor the study, each survey participant received five patient cases from the BRAVE (Bronchial Sample Collection for a Novel Genomic Test) study and was asked to determine an ILD diagnosis, their confidence level in their diagnosis and the next management step. A cohort of 81 physicians initially reviewed cases without Envisia test results (pre-Envisia) and then again with the classifier results added (post-Env...